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Diabetic patients have long been identified to be at high
risk of restenosis and reintervention with bare-metal
stents (BMS) (1). Drug-eluting stents (DES) have been
shown in multiple clinical trials to decrease restenosis
compared with BMS, including in diabetic patients, and
remain the treatment of choice for diabetic percutaneous
revascularization.
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However, there are certain clinical situations in which
clinicians will avoid the use of DESs in patients, particularly
due to the requirement for long-term dual antiplatelet
therapy (DAPT). After DES implantation, current U.S.
and European guidelines recommend 12 months and 6 to
12 months of DAPT, respectively (2,3). Patients with atrial
fibrillation who receive a DES require both DAPT and
anticoagulant therapy, a practice known to substantially
increase the risk of bleeding (4). The need for surgery
necessitating interruption of DAPT or concern about pa-
tient compliance of DAPT may also trigger a decision to use
a BMS. A strategy to avoid DES use in patients at high risk
of bleeding or interruption of DAPT, without paying the
price for restenosis and reintervention, is certainly desirable.
Currently, clinicians have several options for this thera-
peutic dilemma. Recent data suggest that third-generation
DESs may be safer than earlier DESs for the risk of stent
thrombosis and require a shorter (3 months) period of
DAPT (5,6). Several metabolic and device strategies to
reduce restenosis have also been tested with varying out-
comes in diabetic patients treated with a BMS. In the
STREAM (Stent Restenosis and Metabolism) trial, we
were unable to show differences in restenosis rates by
improving glycemic control with a daily dose of insulin (7).
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contents of this paper to disclose.However, the paclitaxel drug–eluting balloon appears to be
an attractive option to prevent restenosis, either when
combined with a chromium cobalt BMS during the initial
revascularization procedure (8) or as a treatment to prevent
a further recurrence of restenosis in patients in whom
restenosis developed with either a BMS or DES (9,10).
Based on the report in this issue of the Journal, oral colchicine
may be yet another consideration to limit restenosis rates in
diabetic patients who are treated with BMSs (11).
Deftereos et al. (11) enrolled 222 diabetic patients at 3
institutions who were considered to have contraindications
to prolonged DAPT, predominantly atrial fibrillation or
planned urgent surgery. All patients received a BMS and
were randomized to either colchicine 0.5 mg twice daily or
placebo. Angiographic in-stent restenosis, defined as diam-
eter stenosis 50%, was reduced by half in the colchicine-
treated group (16% vs. 33% in the control group). The late
lumen loss was 2-fold higher in the control group. Intra-
vascular ultrasound–defined in-stent restenosis, defined as
in-stent a minimum lumen area 4 mm2, was decreased by
44% in the colchicine-treated patients. Overall tolerability
was fair, with premature discontinuation of medication
reported in 16% of colchicine-treated patients.
The imaging results in this trial are impressive, particu-
larly because 2 clinical restenosis trials reported negative
results of colchicine as an anti-restenosis agent in patients
treated with balloon angioplasty in the early 1990s (12,13).
The authors speculated that the explanation for this salutary
effect in stenting rather than balloon angioplasty is due to
the effectiveness of colchicine in preventing intimal hyper-
plasia (14), rather than the negative remodeling that is a
major mechanism of restenosis after balloon angioplasty.
This is speculative and deserves further study.
Should there be immediate and widespread adoption of
colchicine in diabetic patients to prevent restenosis in
patients requiring BMS placement? Most clinical cardiolo-
gists are familiar with colchicine due to its frequent use in
treatment of patients with pericarditis. Nevertheless, clini-
cians should remain cautious about instituting the use of
colchicine for diabetic patients treated with a BMS. As the
authors acknowledged, more studies are required to confirm
a clinical benefit of colchicine in this setting. Of particular
importance, despite the angiographic and intravascular ul-
trasound differences, both the colchicine and placebo groups
had similar and very low levels of revascularization (only
4.5% in the placebo group). Recent data suggested that
reintervention rates in noninsulin-dependent diabetic pa-
tients implanted with a BMS may be lower than previously
assumed. Woudstra et al. (14) reported similar reinterven-
tion rates in both nondiabetic patients and noninsulin-
requiring diabetic patients at 6.3% and 5.6%, respectively.
Whether these results are due to greater use of newer
chromium cobalt BMS or to other periprocedural factors is
not known. These data, along with newer treatment modali-
ties, such as drug-eluting balloons and possibly colchicine,
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patients undergoing interventions with BMS are no longer
no-option patients destined to experience restenosis.
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